Vyleesi (Bremelanotide) Geriatric Dosing: What Clinicians and Patients 65+ Need to Know

Why Bremelanotide Has No Geriatric-Specific Dose

The FDA approved bremelanotide in June 2019 exclusively for premenopausal women with acquired, generalized HSDD [1]. That label excludes postmenopausal women entirely. The two Phase III RECONNECT trials (N=1,247 combined) enrolled women aged 18 to 56, with a mean age near 39 years [2]. No participant over 56 was included.

This means zero controlled efficacy or safety data exist for patients 65 and older. The prescribing information states that "clinical studies of Vyleesi did not include sufficient numbers of patients aged 65 and over to determine whether they respond differently from younger patients" [3]. Without this data, a formal geriatric dose recommendation cannot be issued by the manufacturer. Any use in older adults represents off-label prescribing that should be guided by pharmacokinetic first principles and individualized clinical judgment.

The absence of data is not the same as evidence of harm. But for a YMYL decision, the distinction matters: clinicians prescribing bremelanotide to a 68-year-old patient are operating without the safety net of a controlled trial population that resembles their patient.

Pharmacokinetics in Aging: What Changes After 65

Bremelanotide's pharmacokinetic profile raises specific concerns in older adults. The drug reaches peak plasma concentration (Tmax) approximately one hour after subcutaneous injection, with a terminal half-life of 2.7 hours in healthy premenopausal women [3]. Three renal and hepatic changes common in aging alter this profile.

Renal excretion dominates clearance. Approximately 64.8% of a bremelanotide dose is recovered unchanged in urine [3]. Age-related GFR decline (roughly 1 mL/min/year after age 40, per the Baltimore Longitudinal Study of Aging) means a 70-year-old patient with a GFR of 55 mL/min may clear the drug 40% more slowly than the trial population [4]. This prolongs drug exposure and potentially intensifies both therapeutic and adverse effects.

Hepatic metabolism plays a secondary role. Bremelanotide undergoes hydrolysis by non-specific peptidases rather than CYP450-mediated metabolism [3]. Age-related hepatic blood flow reduction (25-40% by age 75, per published pharmacogeriatric data) may modestly decrease first-pass clearance of the non-renal fraction [5].

Volume of distribution shifts. Older adults carry proportionally more adipose tissue and less lean mass. Bremelanotide is a hydrophilic heptapeptide with a volume of distribution of 51.8 L [3]. Body composition changes could concentrate the drug in a smaller aqueous compartment, yielding higher peak concentrations per unit dose.

Blood Pressure: The Primary Safety Concern in Older Adults

The FDA label carries a specific warning: bremelanotide causes a transient increase in systolic blood pressure (mean 6 mmHg) and diastolic blood pressure (mean 3 mmHg), peaking 2-3 hours post-dose and resolving within 12 hours [3]. In younger, normotensive women, this increase is clinically insignificant. In a 72-year-old patient already on two antihypertensives with a resting BP of 142/88, the calculus changes entirely.

The 2017 ACC/AHA Hypertension Guideline defines Stage 2 hypertension at 140/90 mmHg and higher, and notes that cardiovascular event risk per mmHg of systolic increase is steeper in adults over 65 [6]. A transient 6 mmHg spike layered onto baseline elevation could theoretically trigger a hypertensive urgency in vulnerable patients, particularly those with aortic stiffness or isolated systolic hypertension.

The prescribing information explicitly contraindicates bremelanotide in patients with "uncontrolled hypertension" and advises against use in patients with cardiovascular disease [3]. For geriatric patients, the following pre-prescribing assessment is reasonable:

• Obtain ambulatory blood pressure monitoring or serial home readings over 7 days
• Document cardiovascular risk using the Pooled Cohort Equations or QRISK3
• Ensure blood pressure is consistently below 130/80 before considering use
• Plan post-dose BP monitoring during the first administration

Dr. Sheryl Kingsberg, a lead investigator on the RECONNECT trials, has stated: "Bremelanotide was studied in a very specific population. Extrapolating to populations with significant cardiovascular comorbidity requires extreme caution" [2].

Nausea and Dehydration Risk in Geriatric Patients

Nausea is the most common adverse event with bremelanotide, occurring in 40.0% of treated patients versus 1.3% on placebo in the RECONNECT trials [2]. Among those experiencing nausea, 13% used antiemetic therapy. The nausea is dose-dependent, typically begins within 30 minutes of injection, and resolves within 2-4 hours.

For older adults, nausea carries downstream risks that younger patients do not face to the same degree. Reduced thirst perception (documented in adults over 65 in Age and Ageing research) combined with nausea-driven fluid avoidance can precipitate acute dehydration [7]. This dehydration sequence may trigger orthostatic hypotension, increasing fall risk. The CDC reports that falls remain the leading cause of injury-related death in Americans 65 and older [8].

The cascade: bremelanotide injection causes nausea, nausea reduces oral intake, dehydration follows, orthostatic hypotension develops, and a fall occurs. Each link in this chain is more probable in a geriatric patient than in the 39-year-old mean-age trial participant.

Ondansetron 4 mg given 30 minutes before bremelanotide may mitigate nausea, but introduces its own considerations: QTc prolongation risk increases with age, and the 2023 Beers Criteria update flags ondansetron for caution in patients with cardiac conduction abnormalities [9].

Polypharmacy and Drug-Drug Interactions

Adults 65 and older take a median of 5 prescription medications. Bremelanotide's interaction profile is relatively narrow because it avoids CYP450 metabolism, but two interaction pathways deserve attention in geriatric polypharmacy [3].

Naltrexone interaction. Bremelanotide's FDA label reports a 25% reduction in bremelanotide exposure when co-administered with naltrexone [3]. Naltrexone is prescribed for alcohol use disorder and is increasingly used off-label in low-dose formulations for chronic pain in older adults. Patients on naltrexone may experience reduced bremelanotide efficacy without a dose-adjustment pathway, since exceeding 1.75 mg is not recommended.

Antihypertensive potentiation. While bremelanotide raises blood pressure transiently, the compensatory baroreceptor response and subsequent resolution could interact unpredictably with calcium channel blockers, ACE inhibitors, or alpha-blockers that are actively lowering BP. No formal interaction study has been conducted with common geriatric antihypertensives [3]. The theoretical risk is a rebound hypotensive episode once bremelanotide's pressor effect resolves while background antihypertensives continue working.

Antiemetics and sedatives. If ondansetron or promethazine is used to manage bremelanotide-induced nausea, both carry sedation and QTc risks that compound with other sedating or QTc-prolonging medications common in geriatric regimens (SSRIs, trazodone, fluoroquinolones).

A medication reconciliation reviewing all standing prescriptions against these three interaction categories should precede any bremelanotide prescription in a patient over 65.

Off-Label Context: Why Would a 65+ Patient Receive Bremelanotide?

The question is valid. Bremelanotide is FDA-approved only for premenopausal HSDD. Why discuss geriatric use at all?

Sexual desire complaints persist well beyond menopause. The PRESIDE study (N=31,581) found that 8.9% of women aged 57-85 reported distressing low sexual desire [10]. The Women's Health Initiative reported that 40% of women aged 60-79 considered sexuality moderately to extremely important [11]. Yet approved pharmacotherapy options for postmenopausal HSDD are limited to flibanserin (Addyi), which also lacks geriatric data.

Some clinicians have begun prescribing bremelanotide off-label to postmenopausal women, including those over 65, who have failed flibanserin or who prefer as-needed dosing over daily medication. The Endocrine Society's 2019 guideline on female sexual dysfunction acknowledges the unmet therapeutic need in older women but does not endorse off-label bremelanotide use in this population [12].

This prescribing pattern exists in clinical practice. Clinicians who choose this path should document the off-label rationale, obtain informed consent specifying the absence of geriatric trial data, and implement closer monitoring than would be standard for the approved population.

Proposed Monitoring Protocol for Off-Label Geriatric Use

No published guideline covers bremelanotide monitoring in patients 65+. Based on pharmacokinetic principles, the drug's known adverse effect profile, and geriatric medicine standards, the following monitoring framework is reasonable for clinicians who elect to prescribe off-label.

Before first dose:

• Comprehensive metabolic panel with eGFR calculation (CKD-EPI equation)
• Baseline resting blood pressure (average of 3 readings, seated)
• ECG if patient takes any QTc-prolonging medication
• Falls risk assessment using the Timed Up and Go test or equivalent
• Medication reconciliation with specific attention to naltrexone, antihypertensives, and sedating drugs
• Documented informed consent noting off-label status and absent geriatric data

First dose (supervised):

• Administer in clinic with blood pressure monitoring at 0, 30, 60, and 120 minutes post-injection
• Assess nausea severity using a visual analog scale
• Document orthostatic vitals before discharge

Ongoing (if continued):

• Renal function reassessment every 6 months
• Blood pressure log (home monitoring) for the first month of use
• Patient-reported outcome measure for sexual desire (e.g., FSFI desire domain) at baseline and 8 weeks
• Fall event tracking at each follow-up visit
• Limit to 8 doses per month per label; consider starting with 4 doses monthly to assess tolerability

Renal Impairment: When to Avoid Bremelanotide Entirely

The FDA label does not provide dose adjustments for renal impairment because no dedicated renal impairment study was conducted [3]. Given that 64.8% of the drug is renally eliminated, patients with GFR below 30 mL/min (Stage 4 CKD) face the highest risk of drug accumulation.

The National Kidney Foundation's Kidney Disease Outcomes Quality Initiative recommends that renally cleared drugs without dose-adjustment data should be used with extreme caution in patients with GFR below 30 mL/min and avoided entirely in patients on dialysis unless therapeutic drug monitoring is feasible [13]. Bremelanotide has no validated assay for clinical therapeutic drug monitoring.

A reasonable threshold: GFR below 30 mL/min represents a relative contraindication. GFR 30-59 mL/min warrants starting with supervised first dosing and extended post-dose monitoring (up to 6 hours rather than the standard 2-3 hours for resolution of cardiovascular effects).

Melanocortin Pathway Considerations in Aging

Bremelanotide acts primarily on melanocortin-4 receptors (MC4R) in the central nervous system to promote sexual arousal [3]. MC4R density and signaling efficiency change with aging, though human data on age-related MC4R downregulation remain limited.

Animal studies published in the Journal of Neuroendocrinology have demonstrated reduced hypothalamic MC4R expression in aged rodents [14]. If analogous changes occur in humans, older patients may require either higher receptor occupancy (not achievable with the fixed 1.75 mg dose) or may simply respond less robustly to bremelanotide than younger patients.

Bremelanotide also activates MC1R, which stimulates melanogenesis. Focal hyperpigmentation (reported in 1% of trial participants) could theoretically be more clinically significant in older adults with actinic damage or a history of melanocytic lesions, though no data confirm increased melanoma risk [3]. Annual dermatologic skin checks are a reasonable precaution for geriatric patients using bremelanotide.

What the Data Gap Means for Patients

The absence of geriatric bremelanotide data reflects a broader problem in sexual medicine research. The 2016 Lancet Commission on sexual health noted that "older adults are systematically excluded from sexual health trials despite maintaining sexual interest and activity into the eighth and ninth decades of life" [15]. The RECONNECT trials excluded women over 56 not because of a specific safety signal, but because the approved indication targets premenopausal women by definition.

Until a manufacturer-sponsored or investigator-initiated trial enrolls adults 65+ (for which no registered protocol exists on ClinicalTrials.gov as of May 2026), prescribers must extrapolate from younger populations. That extrapolation demands conservative assumptions about clearance, adverse effects, and monitoring intensity.

For patients 65+ who inquire about bremelanotide: the drug exists, it has a plausible mechanism, and it has zero data supporting safety or efficacy in your age group. Start any discussion there.